24/7 Market News Snapshot 14 May, 2025 – Incannex Healthcare Limited American Depositary Shares (NASDAQ:IXHL)

May 14, 2025

DENVER, Colo., 14 May, 2025 (www.247marketnews.com) – (NASDAQ:IXHL) are discussed in this article.
Incannex Healthcare Limited (IXHL) is experiencing a remarkable surge in its stock price, reaching $0.221 in pre-market trading, which reflects an impressive increase of 159.1% from the previous closing price of $0.085. The substantial trading volume of 46.78 million shares underscores a growing interest among investors, indicating significant market enthusiasm and potential growth opportunities for the healthcare company.

In a related development, Incannex has successfully completed patient dosing in the Phase 2 segment of its Phase 2/3 RePOSA study. This study evaluates the efficacy of IHL-42X, an innovative oral treatment designed for obstructive sleep apnea (OSA). The completion of dosing is a significant milestone, with follow-up assessments expected to conclude by May 17, 2025, and topline results anticipated for release in July 2025.

Joel Latham, President and CEO of Incannex, expressed enthusiasm for the progress of the IHL-42X program, emphasizing its growing momentum as preparations for data analysis commence. He noted the critical impact of OSA on millions globally, highlighting IHL-42X’s potential to serve as a groundbreaking alternative to existing mechanical treatments, particularly for the two-thirds of OSA patients who are not obese.

IHL-42X is a unique combination of dronabinol and acetazolamide, aimed at addressing intermittent hypoxia and hypercapnia—key factors in OSA. Previous Phase 2 trials demonstrated its efficacy, with a noteworthy average reduction of 51% in the Apnea-Hypopnea Index. Responding to substantial enthusiasm from clinical sites and participants, the forthcoming Phase 3 study will concentrate on selected sites to enhance operational efficiency and engagement, while the company also explores preliminary commercial partnerships to maximize the therapeutic potential of IHL-42X.

As Incannex continues its trajectory, the impending results from the RePOSA study are anticipated to solidify the company’s standing as a leader in OSA treatment, paving the way for innovative solutions for patients globally.

Related news for (IXHL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.